A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
Brief description of study
The purpose of this trial is to evaluate whether the addition of epcoritamab to R-CHOP can improve outcomes versus R-CHOP alone in first-line therapy of high-risk DLBCL patients.
Clinical Study Identifier: s20-02024
ClinicalTrials.gov Identifier: NCT05578976
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
